Recently, Huarong Sci-Tech Innovation Biotechnology (Tianjin) Co., Ltd. announced the completion of its Series A financing round, raising over 100 million yuan. This round of financing was led by Biling Capital, with HaoYue Capital serving as the exclusive financial advisor. As the group's first round of financing, the funds will be used for cutting-edge technology research and development, integration of industry-academia-research, transformation of innovative achievements, and expansion into overseas markets, driving high-quality development of the medical industry.
